Mutations in MPNs: Prognostic implications, window to biology, and impact on treatment decisions

Jamile M. Shammo*, Brady L. Stein

*Corresponding author for this work

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

The last decade has witnessed tremendous scientific advances, ushered in by the JAK2 V617F discovery, contributing to enhanced diagnostic capability and understanding of the biology of myeloproliferative neoplasms (MPNs). Discovery of the calreticulin mutations filled a diagnostic gap; more recent work sheds light on its contribution to disease pathogenesis, and prognosis. Recent studies have also identified novel JAK2 and MPL mutations in patients with essential thrombocythemia and myelofibrosis (MF). Especially in MF, the driver mutational profile has prognostic implications, with additive contributions from the acquisition of additional somatic mutations. The hope is that sophisticated molecular profiling will not only aid in prognostication, but also guide selection of therapy for patients with MPNs.

Original languageEnglish (US)
Pages (from-to)552-560
Number of pages9
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - 2016

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Mutations in MPNs: Prognostic implications, window to biology, and impact on treatment decisions'. Together they form a unique fingerprint.

  • Cite this